Nadroparin calcium

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 450486588

| IUPAC_name = (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate

| image = File:Heparin General Structure V.1.svg

| tradename = Fraxiparin(e), Fraxodi, others

| Drugs.com = {{drugs.com|international|nadroparin-calcium}}

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU = S4

| legal_CA = Rx-only

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration = Subcutaneous injection (except for haemodialysis)

| bioavailability = 89% (SC dose)

| protein_bound =

| metabolism =

| elimination_half-life = 3.7 hours (SC dose)

| excretion = clearance 21.4mL/min (+/- 7)

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 9005-49-6

| UNII_Ref = {{fdacite|changed|FDA}}

| UNII = 1K5KDI46KZ

| ATC_prefix = B01

| ATC_suffix = AB06

| PubChem =

| DrugBank_Ref = {{drugbankcite|changed|drugbank}}

| DrugBank = DB08813

| KEGG_Ref = {{keggcite|changed|kegg}}

| KEGG = D07510

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL =

| chemical_formula =

| molecular_weight = 4300

| molecular_weight_comment = g/mol

}}

Nadroparin (trade names Fraxiparin[e], Fraxodi, among others) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by Sanofi-Synthélabo.

Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.{{cite web|title=Fraxiparine PRODUCT MONOGRAPH (Canada)|url=http://www.aspripharma.com/pdf/Fraxiparine%20&%20Fraxi%20Forte%20PM_EN.pdf|website=Aspripharma.com|access-date=2 April 2019}}

For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the abdomen. It is on the World Health Organization's List of Essential Medicines.{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 22nd list (2021) | year = 2021 | hdl = 10665/345533 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2021.02 | hdl-access=free }}